Market Overview

Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

Share:
Related SNY
ENGAGE Randomized Clinical Trial Evaluating Cerdelgafor Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association
Sanofi Posts Higher Q4 Profit
Tracking The Hotchkis & Wiley Value Opportunities Fund: Q4 2014 Update (Seeking Alpha)

Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

Posted-In: News

 

Related Articles (SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content